Promises of targeted therapy for low grade gliomas in children

Low grade gliomas are the most common brain tumors in children. Total resection for operable lesion helps to achieve local and system control. Nevertheless, for inaccessible tumors are required more effective treatment both to overcome the refractory course of the disease, and to mi nimize toxicity...

Full description

Saved in:
Bibliographic Details
Main Authors: E. F. Valiakhmetova, L. A. Yasko, L. I. Papusha, A. E. Druy, A. I. Karachunsky
Format: Article
Language:Russian
Published: ABV-press 2019-07-01
Series:Успехи молекулярной онкологии
Subjects:
Online Access:https://umo.abvpress.ru/jour/article/view/216
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688406504767488
author E. F. Valiakhmetova
L. A. Yasko
L. I. Papusha
A. E. Druy
A. I. Karachunsky
author_facet E. F. Valiakhmetova
L. A. Yasko
L. I. Papusha
A. E. Druy
A. I. Karachunsky
author_sort E. F. Valiakhmetova
collection DOAJ
description Low grade gliomas are the most common brain tumors in children. Total resection for operable lesion helps to achieve local and system control. Nevertheless, for inaccessible tumors are required more effective treatment both to overcome the refractory course of the disease, and to mi nimize toxicity with conventional adjuvant chemotherapy and various types of radiation therapy. In recent years, there has been an accelerated understanding of the molecular pathogenesis of some tumors in children, including low grade gliomas. Given the fact that the basis of the molecular pathogenesis of the low grade gliomas is the activation of signaling pathways MARK (mitogen activated protein kinase) and mTOR (mammalian target of rapamycin), the most promising targeted agents are BRAF, MEK and mTOR inhibitors. Nevertheless, a number of other agents have been studied to find promising targeted therapy for this tumors type. This article summarizes the latest literature evaluating new drugs in low grade glioma.
format Article
id doaj-art-e6fae0a208404fa4b979278f2b3c1205
institution DOAJ
issn 2313-805X
2413-3787
language Russian
publishDate 2019-07-01
publisher ABV-press
record_format Article
series Успехи молекулярной онкологии
spelling doaj-art-e6fae0a208404fa4b979278f2b3c12052025-08-20T03:22:00ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872019-07-0162284110.17650/2313-805X-2019-6-2-28-41160Promises of targeted therapy for low grade gliomas in childrenE. F. Valiakhmetova0L. A. Yasko1L. I. Papusha2A. E. Druy3A. I. Karachunsky4N.N. Burdenko National Scientific and Practical Center for Neurosurgery , Ministry of Health of RussiaDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and ImmunologyDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; N.I. Pirogov Russian National Research Medical UniversityLow grade gliomas are the most common brain tumors in children. Total resection for operable lesion helps to achieve local and system control. Nevertheless, for inaccessible tumors are required more effective treatment both to overcome the refractory course of the disease, and to mi nimize toxicity with conventional adjuvant chemotherapy and various types of radiation therapy. In recent years, there has been an accelerated understanding of the molecular pathogenesis of some tumors in children, including low grade gliomas. Given the fact that the basis of the molecular pathogenesis of the low grade gliomas is the activation of signaling pathways MARK (mitogen activated protein kinase) and mTOR (mammalian target of rapamycin), the most promising targeted agents are BRAF, MEK and mTOR inhibitors. Nevertheless, a number of other agents have been studied to find promising targeted therapy for this tumors type. This article summarizes the latest literature evaluating new drugs in low grade glioma.https://umo.abvpress.ru/jour/article/view/216low grade gliomastargeted therapybraf:kiaa1549 fusionbrafv600 mutationsubependymal giant cell astrocytomamtortyrosine kinase inhibitor
spellingShingle E. F. Valiakhmetova
L. A. Yasko
L. I. Papusha
A. E. Druy
A. I. Karachunsky
Promises of targeted therapy for low grade gliomas in children
Успехи молекулярной онкологии
low grade gliomas
targeted therapy
braf:kiaa1549 fusion
brafv600 mutation
subependymal giant cell astrocytoma
mtor
tyrosine kinase inhibitor
title Promises of targeted therapy for low grade gliomas in children
title_full Promises of targeted therapy for low grade gliomas in children
title_fullStr Promises of targeted therapy for low grade gliomas in children
title_full_unstemmed Promises of targeted therapy for low grade gliomas in children
title_short Promises of targeted therapy for low grade gliomas in children
title_sort promises of targeted therapy for low grade gliomas in children
topic low grade gliomas
targeted therapy
braf:kiaa1549 fusion
brafv600 mutation
subependymal giant cell astrocytoma
mtor
tyrosine kinase inhibitor
url https://umo.abvpress.ru/jour/article/view/216
work_keys_str_mv AT efvaliakhmetova promisesoftargetedtherapyforlowgradegliomasinchildren
AT layasko promisesoftargetedtherapyforlowgradegliomasinchildren
AT lipapusha promisesoftargetedtherapyforlowgradegliomasinchildren
AT aedruy promisesoftargetedtherapyforlowgradegliomasinchildren
AT aikarachunsky promisesoftargetedtherapyforlowgradegliomasinchildren